Literature DB >> 19841538

The APCs of neuroprotection.

Charles T Esmon1, Jonathan D Glass.   

Abstract

Mutations in the enzyme superoxide dismutase 1 (SOD1) have been linked to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). In this issue of the JCI, Zhong et al. report that the endogenous anticoagulant activated protein C (APC) is able to cross the blood-spinal cord barrier in mice and signal to both neuronal and non-neuronal cells (see the related article beginning on page 3437). This signaling resulted in the suppression of mutant SOD1 synthesis and retarded disease progression in a murine model of ALS. Here we discuss the potential importance of these data and possible relevance to human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841538      PMCID: PMC2769189          DOI: 10.1172/JCI40682

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

Review 1.  The cytoprotective protein C pathway.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

2.  Cerebrospinal fluid (CSF) findings in amyotrophic lateral sclerosis.

Authors:  A Leonardi; G Abbruzzese; L Arata; L Cocito; M Vische
Journal:  J Neurol       Date:  1984       Impact factor: 4.849

3.  Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation.

Authors:  A Mizutani; K Okajima; M Uchiba; T Noguchi
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

4.  Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway.

Authors:  Z Laszik; A Mitro; F B Taylor; G Ferrell; C T Esmon
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

5.  Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis.

Authors:  Berend Isermann; Ilya A Vinnikov; Thati Madhusudhan; Stefanie Herzog; Muhammed Kashif; Janusch Blautzik; Marcus A F Corat; Martin Zeier; Erwin Blessing; Jun Oh; Bruce Gerlitz; David T Berg; Brian W Grinnell; Triantafyllos Chavakis; Charles T Esmon; Hartmut Weiler; Angelika Bierhaus; Peter P Nawroth
Journal:  Nat Med       Date:  2007-11-04       Impact factor: 53.440

6.  The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells.

Authors:  Jong-Sup Bae; Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Blood       Date:  2007-09-06       Impact factor: 22.113

7.  Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets.

Authors:  May H Han; Sun-Il Hwang; Dolly B Roy; Deborah H Lundgren; Jordan V Price; Shalina S Ousman; Guy Haskin Fernald; Bruce Gerlitz; William H Robinson; Sergio E Baranzini; Brian W Grinnell; Cedric S Raine; Raymond A Sobel; David K Han; Lawrence Steinman
Journal:  Nature       Date:  2008-02-17       Impact factor: 49.962

8.  Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement.

Authors:  Geerte L Van Sluis; Tatjana M H Niers; Charles T Esmon; Wikky Tigchelaar; Dick J Richel; Harry R Buller; Cornelis J F Van Noorden; C Arnold Spek
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

9.  Activated protein C signals through the thrombin receptor PAR1 in endothelial cells.

Authors:  Matthias Riewald; Ramona J Petrovan; Aaron Donner; Wolfram Ruf
Journal:  J Endotoxin Res       Date:  2003

10.  Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells.

Authors:  Zhihui Zhong; Hristelina Ilieva; Lee Hallagan; Robert Bell; Itender Singh; Nicole Paquette; Meenakshisundaram Thiyagarajan; Rashid Deane; Jose A Fernandez; Steven Lane; Anna B Zlokovic; Todd Liu; John H Griffin; Nienwen Chow; Francis J Castellino; Konstantin Stojanovic; Don W Cleveland; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2009-10-19       Impact factor: 14.808

View more
  6 in total

Review 1.  Cytoprotective protein C pathways and implications for stroke and neurological disorders.

Authors:  Berislav V Zlokovic; John H Griffin
Journal:  Trends Neurosci       Date:  2011-02-25       Impact factor: 13.837

2.  An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Authors:  Yaoming Wang; Zhenggang Zhang; Nienwen Chow; Thomas P Davis; John H Griffin; Michael Chopp; Berislav V Zlokovic
Journal:  Stroke       Date:  2012-07-17       Impact factor: 7.914

3.  Amyloid β suppresses protein C activation through inhibition of the endothelial protein C receptor (EPCR).

Authors:  Xiaolong Zhang; Lei Huang; Gang Lu; Liang Ge; Yong Hong; Zhou Hu
Journal:  J Mol Neurosci       Date:  2013-09-27       Impact factor: 3.444

Review 4.  Rolling back neutrophil adhesion.

Authors:  Rodger P McEver
Journal:  Nat Immunol       Date:  2010-04       Impact factor: 25.606

5.  Endothelial and Astrocytic Support by Human Bone Marrow Stem Cell Grafts into Symptomatic ALS Mice towards Blood-Spinal Cord Barrier Repair.

Authors:  Svitlana Garbuzova-Davis; Crupa Kurien; Avery Thomson; Dimitri Falco; Sohaib Ahmad; Joseph Staffetti; George Steiner; Sophia Abraham; Greeshma James; Ajay Mahendrasah; Paul R Sanberg; Cesario V Borlongan
Journal:  Sci Rep       Date:  2017-04-13       Impact factor: 4.379

6.  Human Bone Marrow Endothelial Progenitor Cell Transplantation into Symptomatic ALS Mice Delays Disease Progression and Increases Motor Neuron Survival by Repairing Blood-Spinal Cord Barrier.

Authors:  Svitlana Garbuzova-Davis; Crupa Kurien; Edward Haller; David J Eve; Stephanie Navarro; George Steiner; Ajay Mahendrasah; Surafuale Hailu; Mohammed Khatib; Kayla J Boccio; Cesario V Borlongan; Harry R Van Loveren; Stanley H Appel; Paul R Sanberg
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.